Bloom F L, Cohan R H, Leifer K N, Spangler D L, Rhoades R B, Wittig H J
Ann Allergy. 1977 Jun;38(6):408-12.
A double-blind, crossover study was performed with a new topical aerosol steroid, flunisolide, administered every 12 hours over a period of eight weeks to 36 adult patients with perennial allergic rhinitis. During the treatment period the majority of patients had significant relief of symptoms as compared with the placebo period. Most prominent improvement occurred with the symptoms of nasal stuffiness, sneezing, rhinorrhea and the number of times patients had to blow their noses. Best results were obtained in patients with higher degrees of atopy. Side effects were minimal and limited to nasal irritation in some patients. Criteria for optimal patient selection are discussed and an explanation for the lack of systemic effects of aerosolized use of the newer corticosteroids is given.
对36名常年性变应性鼻炎成年患者进行了一项双盲交叉研究，使用一种新的局部气雾剂类固醇氟尼缩松，每12小时给药一次，为期八周。在治疗期间，与使用安慰剂的时期相比，大多数患者的症状得到了显著缓解。鼻塞、打喷嚏、流涕症状以及患者擤鼻涕的次数改善最为明显。特应性程度较高的患者取得了最佳效果。副作用极小，仅在部分患者中出现鼻腔刺激症状。文中讨论了最佳患者选择标准，并对新型皮质类固醇气雾剂使用缺乏全身效应的原因进行了解释。
